NCT02249091 2021-08-25
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
GSO Global Clinical Research BV
Phase 2 Completed
Clinical Trials
6 trialsNCT03661515 2020-05-20
FLAGINEXOR
PETHEMA Foundation
Phase 1 Completed
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02652871 2019-11-15
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01692197 2018-07-03
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00382954 2010-09-29
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
University of Kentucky
Phase 1 Completed